Deep within Romania's Apuseni mountain range lies the Scărișoara Ice Cave, home to a substantial body of perennial ice. Recent research has unveiled a fascinating discovery: a living bacterium, named Psychrobacter SC65A.3, that has been preserved in this icy environment for approximately 5,000 years. Remarkably, this ancient microbe demonstrates resistance to numerous modern antibiotics.
This unique bacterium was extracted from ice layers that date back 5,335 years, a testament to the cave's preservation of climatic history over the last 13,000 years. Researchers drilled a 25-meter ice core from the Great Hall area of the cave to access these ancient layers. Upon isolating and sequencing the genome of SC65A.3, scientists identified a circular DNA structure comprising about 3.05 million base pairs and over 2,500 genes, many of which remain uncharacterized.
In laboratory tests involving 28 different antibiotics, SC65A.3 exhibited resistance to 10 of them, including those commonly used for treating severe infections. Researcher Cristina Purcarea emphasized the significance of these findings, noting that the antibiotics to which this bacterium is resistant are widely prescribed in clinical settings.
Potential Implications of Ancient Antibiotic Resistance
The genome analysis revealed 107 genes linked to antimicrobial resistance mechanisms, including those that help bacteria evade the effects of drugs or alter their targets. However, the researchers caution against overinterpreting these resistance profiles, as there are no established medical guidelines for Psychrobacter, making it challenging to predict its real-world implications accurately.
The presence of this resistant bacterium raises intriguing questions about the future of antibiotic resistance. Purcarea noted that if melting ice were to release these microbes, the genes responsible for their resistance could potentially transfer to contemporary bacteria, exacerbating the global challenge of antibiotic resistance.
Interestingly, SC65A.3 not only resists antibiotics but also appears to combat harmful bacteria. In laboratory assays, extracts from this ancient microbe inhibited 14 different pathogens, including notorious hospital-acquired infection agents such as Enterococcus faecium, Pseudomonas aeruginosa, and Klebsiella pneumoniae.
Researchers identified 11 candidate genes associated with the production of antimicrobial compounds, suggesting that SC65A.3 plays a dual role: it is both resistant to last-resort antibiotics and capable of suppressing other resistant strains. This phenomenon aligns with the competitive nature of bacteria in various ecosystems, where they continuously evolve defenses and counter-defenses.
As scientists continue to explore these ancient bacteria, they recognize their potential value for future medical applications while emphasizing the importance of safety measures in laboratory settings to prevent any unintended consequences.